<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584518</url>
  </required_header>
  <id_info>
    <org_study_id>11-16126</org_study_id>
    <nct_id>NCT01584518</nct_id>
  </id_info>
  <brief_title>B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading</brief_title>
  <official_title>B-type Natriuretic Peptide (BNP) as a Surrogate Marker Guiding Post-operative Fluid Off-loading</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-range goal of this proposal is to decrease morbidity and mortality related to
      pulmonary edema and congestive heart failure (CHF) in post-operative patients. The
      short-range goal is to determine a mechanistic endpoint when therapy for impending heart
      failure can be initiated and terminated based on B-type natriuretic peptide (BNP) levels.
      The investigators propose to utilize changing levels of BNP as a surrogate marker for CHF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Creighton University Medical Center is 334-bed Level I Trauma Center that hosts a wide
      variety of surgical and trauma patients. Many of these patients, including and especially
      those with pre-existing cardiac morbidities, develop symptoms of congestive heart failure
      (CHF) following trauma or surgical intervention because of a combination of physiological
      factors including third spacing followed by self-diuresis, and decreased contractility post
      injury. Normally, following the onset of CHF, surgeons begin treatment based on their
      clinical judgment of hemodynamic parameters and radiographic findings. CHF is known to
      increase morbidity, mortality, hospital length of stay and overall expenditure to the health
      care system and preventative measures and directed treatment modalities have potential to
      improve patient care and healthcare economics.

      BNP, also known as beta-natriuretic protein or CHF peptide, is a cardiac neuro-hormone
      synthesized by the cardiac myocytes. It is released as a preproBNP peptide of 134 amino
      acids and is cleaved into proBNP (108 amino acids) and a signal peptide of 26 amino acids.
      ProBNP is subsequently cleaved into BNP (32 amino acids) and the inactive N-terminal proBNP
      peptide (NBNP; 76 amino acids). The effects of BNP are vasodilation, natriuresis and
      diuresis1.

      Left ventricular end-diastolic wall stress (EDWS) measurement and ejection fraction are well
      established surrogates to predict the onset of CHF but require the invasive procedure of
      cardiac catheterization.

      The mainstay of the treatment of CHF is diuretic drugs to try to remove excess fluid from
      the patient. In this project we plan to identify patients at risk for CHF and divide them
      into two groups. In one group BNP will be used to guide diuretic dosage and in the other
      conventional clinical parameters will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>From date of admission until date of discharge, assessed up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The subjects will be evaluated preoperatively and followed post-operatively until discharge from the hospital. Length of stay</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Fluid Over-load</condition>
  <arm_group>
    <arm_group_label>CHF peptide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diuresis based on CHF-P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non CHF peptide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diuresis based on clinical judgement without data for CHF-P</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Based on clinical standard per clinician</description>
    <arm_group_label>CHF peptide</arm_group_label>
    <arm_group_label>Non CHF peptide</arm_group_label>
    <other_name>Brand name: Lasix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General Surgery patients with history of coronary artery disease, congestive heart
             failure, pulmonary hypertension

          -  Cardiac surgery patients undergoing CABG (coronary artery bypass grafting) and valve
             replacements

        Exclusion Criteria:

          1. Recent myocardial infarction (within 3 months).

          2. ASA class 4 and more.

          3. Emergency surgeries.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjan J Talukdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 25, 2016</lastchanged_date>
  <firstreceived_date>April 11, 2012</firstreceived_date>
  <firstreceived_results_date>January 4, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CHF Peptide</title>
          <description>Diuresis based on CHF-P
Furosemide: Based on clinical standard per clinician</description>
        </group>
        <group group_id="P2">
          <title>Non CHF Peptide</title>
          <description>Diuresis based on clinical judgement without data for CHF-P</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CHF Peptide</title>
          <description>Diuresis based on CHF-P
Furosemide: Based on clinical standard per clinician</description>
        </group>
        <group group_id="B2">
          <title>Non CHF Peptide</title>
          <description>Diuresis based on clinical judgement without data for CHF-P</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70" spread="10"/>
                <measurement group_id="B2" value="70" spread="9"/>
                <measurement group_id="B3" value="70" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay</title>
        <description>The subjects will be evaluated preoperatively and followed post-operatively until discharge from the hospital. Length of stay</description>
        <time_frame>From date of admission until date of discharge, assessed up to 1 month</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>CHF Peptide</title>
            <description>Diuresis based on CHF-P
Furosemide: Based on clinical standard per clinician</description>
          </group>
          <group group_id="O2">
            <title>Non CHF Peptide</title>
            <description>Diuresis based on clinical judgement without data for CHF-P</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Stay</title>
            <description>The subjects will be evaluated preoperatively and followed post-operatively until discharge from the hospital. Length of stay</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4" spread="3"/>
                  <measurement group_id="O2" value="6" spread="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <desc>Creatinine levels</desc>
      <group_list>
        <group group_id="E1">
          <title>CHF Peptide</title>
          <description>Diuresis based on CHF-P
Furosemide: Based on clinical standard per clinician</description>
        </group>
        <group group_id="E2">
          <title>Non CHF Peptide</title>
          <description>Diuresis based on clinical judgement without data for CHF-P</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Anjan Talukdar</name_or_title>
      <organization>Creighton University</organization>
      <phone>402-280-3586</phone>
      <email>talukdar.anjan@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
